Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 3/20 | 0.55 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.55 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.55 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.55 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.55 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819659 | 1.00 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5120532 | 1.00 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2822767 | 0.90 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4733079 | 0.90 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5131621 | 0.90 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5119348 | 0.87 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5119350 | 0.87 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2819567 | 0.86 | HTR1D (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5121715 | 0.86 | HTR1D (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2824402 | 0.86 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384968-B2 | Thiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2008-06-10 | — | — | US | claimed |
| EP-1735292-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| US-20060084689-A1 | Thiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC. | 2006-04-20 | — | — | US | claimed |
| WO-2005095367-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20080207712-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-08-28 | — | — | US | disclosed |
| US-7384968-B2 | Thiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1735292-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060084689-A1 | Thiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC. | 2006-04-20 | — | — | US | disclosed |
| WO-2005095367-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207712-A1 | THIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, PSEN1, BACE1 | PSEN1 2/4885PSEN2 5/4885APH1B 83/4885 |
| US-20060084689-A1 | Thiazole-amine compounds for the treatment of neurodegenerative disorders | APP, PSEN1, BACE1 | PSEN1 2/4885PSEN2 5/4885APH1B 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.